Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AbbVie proposes $46bn bid for Shire; fifth offer of $53.3bn accepted; deal terminated in response to new US tax code

Executive Summary

On the heels of Pfizer Inc.’s failed takeover attempt of AstraZeneca PLC, AbbVie Inc. proposed to pay $46bn (£27bn) for Shire PLC, whose stockholders would receive $34.78 in cash and 0.7988 ordinary AbbVie shares for each share held (worth $78.07, a 58% discount). (AbbVie’s initial offer on May 5th valued each Shire share at $65.72 and its second bid on May 14th was $67.35.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies